Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T, Nguyen A, Misleh J, Cline VJ, Johns M, Shumway N, Paulson S, Siegel R, Larson T, Messersmith W, Richards D, Chaves J, Pierce E, Zalupski M, Sahai V, Orr D, Ruste SA, Haun A, Kawabe T. Enzler T, et al. Among authors: messersmith w. Eur J Cancer. 2024 Apr;201:113950. doi: 10.1016/j.ejca.2024.113950. Epub 2024 Feb 22. Eur J Cancer. 2024. PMID: 38422585 Free article. Clinical Trial.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Coveler AL, Reilley MJ, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvisé M, Nagrial A, Uboha NV, Frentzas S, Overman M, Noonan A, Messersmith WA, Pavlakis N, Mettu NB, Bisha I, Wang Y, Smith P, Murtomaki E, Bielska AA, Bragulat V, Cooper ZA, Kumar R, Spigel DR. Coveler AL, et al. Among authors: messersmith wa. Clin Cancer Res. 2024 Oct 15;30(20):4609-4617. doi: 10.1158/1078-0432.CCR-24-0499. Clin Cancer Res. 2024. PMID: 39106081 Free PMC article. Clinical Trial.
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.
Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. Lentz RW, et al. Among authors: messersmith wa. Clin Cancer Res. 2024 Sep 3;30(17):3768-3778. doi: 10.1158/1078-0432.CCR-24-0090. Clin Cancer Res. 2024. PMID: 38869830 Free PMC article. Clinical Trial.
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment.
Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Amo-Aparicio J, et al. Among authors: messersmith wa. Cancer Res Commun. 2023 Sep 20;3(9):1899-1911. doi: 10.1158/2767-9764.CRC-23-0065. Cancer Res Commun. 2023. PMID: 37772994 Free PMC article.
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, Lieu CH, O'Bryant CL, Smoots SG, Dus ED, Jordan KR, Serkova NJ, Pitts TM, Diamond JR. Davis SL, et al. Among authors: messersmith wa. Cancers (Basel). 2024 Apr 10;16(8):1456. doi: 10.3390/cancers16081456. Cancers (Basel). 2024. PMID: 38672538 Free PMC article.
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
Hawkins HJ, Yacob BW, Brown ME, Goldstein BR, Arcaroli JJ, Bagby SM, Hartman SJ, Macbeth M, Goodspeed A, Danhorn T, Lentz RW, Lieu CH, Leal AD, Messersmith WA, Dempsey PJ, Pitts TM. Hawkins HJ, et al. Among authors: messersmith wa. PLoS One. 2024 Apr 10;19(4):e0298808. doi: 10.1371/journal.pone.0298808. eCollection 2024. PLoS One. 2024. PMID: 38598488 Free PMC article.
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial.
Rodon Ahnert J, Tan DS, Garrido-Laguna I, Harb W, Bessudo A, Beck JT, Rottey S, Bahary N, Kotecki N, Zhu Z, Deng S, Kowalski K, Wei C, Pathan N, Laliberte RJ, Messersmith WA. Rodon Ahnert J, et al. Among authors: messersmith wa. ESMO Open. 2023 Aug;8(4):101584. doi: 10.1016/j.esmoop.2023.101584. Epub 2023 Jun 26. ESMO Open. 2023. PMID: 37379764 Free PMC article. Clinical Trial.
215 results